References
Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR . The BCL-2 family reunion. Mol Cell 2010; 37: 299–310.
Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677–681.
Pradelli LA, Beneteau M, Chauvin C, Jacquin MA, Marchetti S, Munoz-Pinedo C et al. Glycolysis inhibition sensitizes tumor cells to death receptors-induced apoptosis by AMP kinase activation leading to Mcl-1 block in translation. Oncogene 2010; 29: 1641–1652.
Warr MR, Shore GC . Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr Mol Med 2008; 8: 138–147.
Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM . The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med 1988; 167: 353–371.
Herrant M, Jacquel A, Marchetti S, Belhacene N, Colosetti P, Luciano F et al. Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene 2004; 23: 7863–7873.
Li G, Miskimen KL, Wang Z, Xie XY, Tse W, Gouilleux F et al. Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycin. Leukemia 2010; 24: 1397–1405.
Bhat UG, Gartel AL . Nucleoside analog ARC targets Mcl-1 to induce apoptosis in leukemia cells. Leukemia 2010; 24: 851–855.
Mason KD, Khaw SL, Rayeroux KC, Chew E, Lee EF, Fairlie WD et al. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia 2009; 23: 2034–2041.
Mason EF, Rathmell JC . Cell metabolism: an essential link between cell growth and apoptosis. Biochim Biophys Acta 2011; 1813: 645–654.
Coloff JL, Macintyre AN, Nichols AG, Liu T, Gallo CA, Plas DR et al. Akt-Dependent Glucose Metabolism Promotes Mcl-1 Synthesis to Maintain Cell Survival and Resistance to Bcl-2 Inhibition. Cancer Res 2011; 71: 5204–5213.
El Mjiyad N, Caro-Maldonado A, Ramirez-Peinado S, Munoz-Pinedo C . Sugar-free approaches to cancer cell killing. Oncogene 2011; 30: 253–264.
Acknowledgements
We thank Joseph T Opferman (St Jude Children's Research Hospital) for Mcl-1−/− MEF, and greatly acknowledge the C3 M animal room facility. This work was supported in part by the Association pour la Recherche sur le Cancer (ARC) and by l’Agence Nationale de la Recherche (ANR-09-JCJC-0003-01). MB is supported by la Fondation pour la Recherche Médicale (FRM), AC is supported by ARC, MJ received a fellowship from la Région PACA, JER and MC are recipients of a contrat d’interface INSERM-CHU de Nice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Meynet, O., Bénéteau, M., Jacquin, M. et al. Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis. Leukemia 26, 1145–1147 (2012). https://doi.org/10.1038/leu.2011.327
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2011.327
- Springer Nature Limited